Compare ClearPoint Neuro Inc (CLPT) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? ClearPoint Neuro Inc trades at $15.78 (market cap $478.63M), while Vanguard Information Technology Index Fund ETF trades at $115.38. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | VGT | |
|---|---|---|
Market Cap | $478.63M | — |
Sector | Health | — |
52-Week High | $29.60 | $125.77 |
52-Week Low | $8.66 | $83.59 |
Enterprise Value | $506.63M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
VGT trades at $115.58, down 2.12% on the day amid a neutral technical signal. The ETF's moving averages show bearish momentum, while oscillators are neutral. Recent news highlights strong 2026 performance against the S&P 500 and ongoing investor interest in tech ETFs, though fee comparisons with competitors like FTEC are noted. A 1:8 stock split occurred in April 2026, with a small dividend scheduled for June 2026.
Outlook remains tied to tech sector strength and AI-driven earnings, but risks include valuation sensitivity and sector volatility. The ETF's low expense ratio and broad diversification offer a cost-effective tech exposure, yet overlap costs and hyperscaler capex guidance in H2 2026 warrant monitoring for potential pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
